Search PubMedSearch

PubMed · 9115016

Increased precision using countermatching in nested case-control studies.

Abstract

Nested case-control studies in occupational cohorts are often used to estimate exposure effects when development of detailed exposure estimates for all cohort members is too costly. Duration of exposure, which can act as a surrogate for cumulative exposure, is often readily available for all cohort members. Langholz and others have recently proposed a method of control selection called countermatching, which uses data on the surrogate to determine which controls are selected from the risk set for a given case. This method may increase precision relative to the usual random sampling of the risk set. We compare countermatching with random sampling in a nested case-control study of silicosis among miners. Data on cumulative exposure were in fact available for all cohort members, enabling estimation of the parameter of interest in the full cohort. We conducted nested case-control analyses using 100, 20, 10, and 3 controls per case using random sampling and additional analyses using 3 controls per case with two different methods of countermatching. All analyses were replicated 50 times to explore the statistical properties of the estimated exposure parameter. We found that one of the countermatching methods markedly increased efficiency compared with random sampling. Countermatching using 3 controls per case yielded an approximate 25% increase in relative efficiency compared with random sampling; it was approximately equivalent to random sampling using 10 controls.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

K Steenland, J A Deddens. 1997. Increased precision using countermatching in nested case-control studies.. https://doi.org/10.1097/00001648-199705000-00002

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Pulmonary hypertension after splenectomy?

BACKGROUND: A high prevalence of asplenia has been observed in patients with unexplained pulmonary hypertension. OBJECTIVE: To describe the clinical and histopathologic characteristics of patients with postsplenectomy pulmonary hypertension and to compare the prevalence of surgical asplenia in patients with idiopathic pulmonary hypertension and patients with other pulmonary diseases. DESIGN: Case series and case-control study. SETTING: University hospital in Hannover, Germany. PATIENTS: 61 patients with pulmonary hypertension and 151 lung transplant recipients. RESULTS: The prevalence of asplenia in patients with pulmonary hypertension was 11.5% (95% CI, 4.7% to 22.2%) compared with 0% (CI, 0% to 3.2%) in those without pulmonary hypertension (P < 0.001). Histopathologic examination of lung specimens from patients with postsplenectomy pulmonary hypertension showed intimal fibrosis, plexiform lesions, and abundant thrombotic lesions. CONCLUSION: Patients who have had splenectomy may be at increased risk for developing pulmonary hypertension.

Case-Control Studies

Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.

BACKGROUND: Most human female cells contain two X chromosomes, only one of which is active. The process of X-chromosome inactivation, which occurs early in development, is usually random, producing tissues with equal mixtures of cells having active X chromosomes of either maternal or paternal origin. However, nonrandom inactivation may occur in a subset of females. If a tumor suppressor gene were located on the X chromosome and if females with a germline mutation in one copy of that suppressor gene experienced nonrandom X-chromosome inactivation, then some or all of the tissues of such women might lack the wild-type suppressor gene function. This scenario could represent a previously unrecognized mechanism for development of hereditary cancers. We investigated whether such a mechanism might contribute to the development of hereditary ovarian cancers. METHODS: Patterns of X-chromosome inactivation were determined by means of polymerase chain reaction amplification of the CAG-nucleotide repeat of the androgen receptor (AR) gene after methylation-sensitive restriction endonuclease digestion of blood mononuclear cell DNA from patients with invasive (n = 213) or borderline (n = 44) ovarian cancer and control subjects without a personal or family history of cancer (n = 50). BRCA1 gene status was determined by means of single-strand conformational polymorphism analysis and DNA sequencing. All statistical tests were two-sided. RESULTS AND CONCLUSIONS: Among individuals informative for the AR locus, nonrandom X-chromosome inactivation was found in the DNA of 53% of those with invasive cancer versus 28% of those with borderline cancer (P = .005) and 33% of healthy control subjects (P = .016). Nonrandom X-chromosome inactivation can be a heritable trait. Nine of 11 AR-informative carriers of germline BRCA1 mutations demonstrated nonrandom X-chromosome inactivation (.0002 < P < .008, for simultaneous occurrence of both). IMPLICATIONS: Nonrandom X-chromosome inactivation may be a predisposing factor for the development of invasive, but not borderline, ovarian cancer.

Case-Control Studies